Quest Laborato.

Who are the top shareholders of the Quest?

The top shareholder of Quest is Anil Kumar Sabarwal, holding 62.29% of the shares, with individual investors owning 24.35% and three foreign institutional investors holding a combined 0.95%. The highest public shareholder is Priti Kamlesh Gandhi, who owns 1.22%.

The top shareholders of Quest include the promoters, with Anil Kumar Sabarwal holding the largest share at 62.29%. There are no pledged promoter holdings, and individual investors collectively hold 24.35% of the shares. Additionally, there are three foreign institutional investors (FIIs) that hold a combined 0.95%. The highest public shareholder is Priti Kamlesh Gandhi, who owns 1.22%.

When is the next results date for Quest?

No Upcoming Board Meetings

Has Quest declared dividend?

No Dividend History Available

Who are the peers of the Quest?

Quest's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sun Pharma and Cipla show excellent management and growth, while Divi's Lab has the highest 1-year return at 51.96%, and Quest's return is 0.00%.

Peers: The peers of Quest are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, BDH Industries, Tyche Industries, Lactose (India), Sotac Pharma., and Vaishali Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Below Average management risk is found at Lactose (India), Sotac Pharma., Vaishali Pharma, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, BDH Industries, Tyche Industries, Lactose (India), Vaishali Pharma, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, BDH Industries, Tyche Industries, while Below Average capital structure is noted for Lactose (India), Sotac Pharma., Vaishali Pharma, and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while BDH Industries has the lowest at -25.45%. Quest's own 1-year return is 0.00%, which is lower than both of these peers. Additionally, Lactose (India), BDH Industries, Tyche Industries, and Vaishali Pharma have negative six-month returns.

What is the technical trend for Quest?

As of May 29, 2025, Quest's technical trend has shifted to bearish, supported by negative indicators from the MACD, Bollinger Bands, and moving averages, with no immediate reversal signals evident.

As of 29 May 2025, the technical trend for Quest has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. The weekly MACD is bearish, and the Bollinger Bands also reflect a bearish trend. Daily moving averages confirm the bearish outlook. The KST on a weekly basis is bearish as well. Overall, the lack of significant signals from the RSI, Dow Theory, and OBV suggests a continuation of the bearish trend without any immediate reversal signals.

What does Quest Laborato. do?

Quest Laboratories Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1998 and publicly listed as of January 2024. It has a market cap of INR 149 Cr, with a P/E ratio of 11.00 and a Return on Equity of 47.36%.

Overview:<BR>Quest Laboratories Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1998 under the name "Quest Laboratories Private Limited." It later changed its status to a Public Limited company and adopted the name "Quest Laboratories Limited" on January 23, 2024. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 149 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 11.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.17<BR>Return on Equity (ROE): 47.36%<BR>Price-to-Book: 5.20<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Quest Laborato.?

As of 24th July, Quest Laboratories Ltd has a market capitalization of 177.00 Cr, classifying it as a Micro Cap company. Recent quarterly performance data is unavailable, but as of March 2024, Shareholder's Funds are valued at 28.64 Cr, and Total Assets amount to 59.29 Cr.

As of 24th July, Quest Laboratories Ltd has a market capitalization of 177.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent quarterly performance data is unavailable, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>In the balance sheet snapshot for the reporting period of March 2024, Shareholder's Funds are valued at 28.64 Cr, and Total Assets amount to 59.29 Cr.

Is Quest Laborato. overvalued or undervalued?

As of September 16, 2025, Quest Laboratories is considered very attractive and undervalued with a PE ratio of 11.35 and strong financial metrics, despite a year-to-date stock decline of 21.27% compared to a 6.74% gain in the Sensex.

As of 16 September 2025, the valuation grade for Quest Laboratories has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, especially when considering its key financial ratios. The PE ratio stands at 11.35, while the EV to EBITDA is 8.47, and the ROCE is a strong 24.38%, showcasing efficient capital utilization.<BR><BR>In comparison to its peers, Quest Laboratories appears favorably positioned. For instance, Sun Pharma has a PE ratio of 33.64, categorizing it as expensive, while Cipla, deemed attractive, has a PE of 23.31. The PEG ratio for Quest is notably at 0.00, suggesting that it may be undervalued relative to its growth potential. Despite recent stock performance lagging behind the Sensex, with a year-to-date decline of 21.27% compared to a 6.74% gain in the index, the underlying financial metrics support a bullish outlook for Quest Laboratories.

How has been the historical performance of Quest Laborato.?

Quest Laborato has shown significant growth from Mar'23 to Mar'25, with net sales increasing from 0.62 Cr to 103.91 Cr and profit after tax rising from 0.05 Cr to 13.57 Cr, despite a negative cash flow of -23.00 Cr in Mar'25. Total assets also grew from 46.94 Cr to 121.65 Cr during this period.

Answer:<BR>The historical performance of Quest Laborato shows significant growth in various financial metrics over the past few years.<BR><BR>Breakdown:<BR>Quest Laborato's net sales have increased from 0.62 Cr in Mar'23 to 103.91 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 0.62 Cr in Mar'23 to 103.91 Cr in Mar'25. The company's total expenditure, excluding depreciation, also rose from 0.53 Cr in Mar'23 to 87.93 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) grew from 0.09 Cr in Mar'23 to 20.22 Cr in Mar'25, showcasing improved profitability, while profit before tax increased from 0.07 Cr in Mar'23 to 18.68 Cr in Mar'25. Profit after tax also saw a substantial rise from 0.05 Cr in Mar'23 to 13.57 Cr in Mar'25. On the balance sheet, total assets grew from 46.94 Cr in Mar'23 to 121.65 Cr in Mar'25, with total liabilities increasing from 46.94 Cr to 30.26 Cr in the same period. The cash flow from operating activities turned negative at -23.00 Cr in Mar'25, contrasting with positive cash flows in previous years. Overall, Quest Laborato has demonstrated robust growth in revenue and profitability, despite challenges in cash flow management.

Are Quest Laboratories Ltd latest results good or bad?

Quest Laboratories Ltd's latest results show strong revenue growth of 68% year-on-year, reaching ₹25.62 crores, but a significant decline in net profit by 33.66% and a drop in operating margin to 13.23% indicate serious profitability concerns, suggesting the overall results are more negative than positive.

Quest Laboratories Ltd's latest results present a mixed picture. On one hand, the company achieved a notable revenue growth of 68.00% year-on-year, with net sales reaching ₹25.62 crores. This indicates strong market demand and effective expansion of its product portfolio. However, this impressive topline growth is overshadowed by significant profitability concerns. <BR><BR>Net profit for the quarter was ₹4.02 crores, which reflects a concerning decline of 33.66% compared to the same quarter last year. Additionally, the operating margin has sharply decreased to 13.23%, down from 32.15% a year ago, indicating that rising costs are eroding profitability despite increased sales. <BR><BR>The stock is currently trading below its key moving averages and has underperformed relative to its peers and the broader market, raising concerns about investor sentiment and future growth prospects. Overall, while the revenue growth is a positive sign, the decline in profitability and margins suggests that the results are more negative than positive, highlighting challenges that the company needs to address moving forward.

Should I buy, sell or hold Quest Laboratories Ltd?

Which are the latest news on Quest Laborato.?

Why is Quest Laboratories Ltd falling/rising?

As of 03-Jun, Quest Laboratories Ltd's stock price is 100.85, down 0.25 (-0.25%), and has significantly underperformed the sector. The stock is in a bearish trend, with a 13.14% decline over the past week and a 33.50% drop in the last month, alongside decreased investor participation indicating low confidence.

As of 03-Jun, Quest Laboratories Ltd's stock price is currently at 100.85, reflecting a decrease of 0.25 (-0.25%). The stock has underperformed compared to the sector by 0.54% today and is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Over the past week, the stock has seen a significant decline of 13.14%, and in the last month, it has dropped by 33.50%, which is considerably worse than the Sensex's decline of 2.10% and 2.47%, respectively.<BR><BR>Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 54.02% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors. Despite some positive factors such as high management efficiency and a healthy long-term growth rate, the current market sentiment appears to be negative, contributing to the stock's downward movement.